Ascendiant raises Outlook Therapeutics target to $10.50
Ascendiant Capital increased its price target on Outlook Therapeutics (OTLK) to $10.50 from $10.00 following the FDA approval of LYTENAVA.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.